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BC023644 A. INTRODUCTION: Human breast carcinoma-induced osteolysis (HBC-IO).
Bone metastasis in human breast carcinoma (HBC) occurs in 83% of patients with advanced disease. Unlike most other types of cancer, breast cancer has a predilection for spreading to the bone, and bone metastasis is a major cause of increased pain, morbidity and mortality. Clinically, bone metastasis causes degeneration of the bone matrix (osteolysis), hypercalcemia, pathologic fracture, and nerve-compression syndrome. The pathophysiology of HBC-IO is not well understood. It is generally thought that HBC-IO is related to an increase in the number and activity of bone resorbing cells, the osteoclasts, at the site of the HBC metastatic lesion. These observations strongly support the involved of cell-to-cell interactions and cytokine networks in HBC-IO. IL-1 has been demonstrated in bone resorption and IL-1 has been shown to be expressed by HBC cells, however a major gap exists in our understanding of processes that occur in HBC-IO and the role of tumor-cell derived IL-1. Rationale/purpose: Since IL-I expression has been correlated with HBC aggressiveness and IL-1 is a known activator of osteoclasts, we propose to study the levels and distribution of the IL-1 family of cytokines and receptors in HBC-IO using patient tissue samples. Objectives: 1. Demonstrate the presence, distribution and levels of the IL-1 family of cytokines and receptors [IL-Ic, IL-1j3, IL-1 receptor antagonist (IL-ira), IL-I RI, and IL-1RII] within the HBC-1O microenvironment using immunohistochemistry and ELISA, 2. Demonstrate the presence, distribution and levels of osteogenic activators/markers of osteolysis (RANKL, PTHrP and OPG) within the HBC-IO microenvironment using immunohistochemistry and ELISA, 3. Quantitate disease/lesion severity using histomorphometry (bone density, osteoclast number and distribution, tumor size and distribution), and 4. Correlate 1, 2, and 3 as described above with clinical diagnosis (primary benign bone lesions vs. primary malignant vs. bone metastasis from breast carcinoma TASK 2. Determine the distribution of the IL-1 family of Table 1 . Panel of 20/22 anti-human antibodies cytokines and receptors in primary benign, primary we have evaluated to examine HBC bone malignant and breast ossous-metastatic samples. metastasis in de-calcified bone samples. The major goal of this program was to determine if the proinflammatory cytokine, Interleukin-1 (IL-1), family of agonists, antagonists and receptors are present in the breast cancer osseous metastatic microenvironment. Furthermore, expression is to be compared to primary bone benign and malignant tumors using IHC. 2b. Research Accomplishments. Since we are exploring a new area where no published research has been done we first needed to define as establish IHC protocols IL-1 x, IL-1f3, IL-I receptor antagonist (IL-1 ra), IL1Receptor I (IL-iRI) and IL-IR11 using paraffin embedded samples that are de-calcified. To accomplish this we evaluated different methods of antigen retrieval using 1. citrate buffer with various heat treatments, 2. 4NHC1, and 3. DeCal Retrieval (BioGenix). Additionally we examined 20/22 different antibodies (Table 1 ) with these methods. The second goal of this task was to determine the expression of IL-1 by cell type and relative staining intensity. The results are summarized in table 2 and figure 1. 2a Problems and Solutions. We wasted one month using the anti-osteoclast Ag antibody supplied from IDS. The technical support documents clearly support the use of this product for both formalin fixed paraffin embedded (FFPE) tissue and frozen section (OCT). The U.S. supplier assured us that it worked with FFPE and would contact technical support in the U.K. regarding this issue. The U.K. division was on "holiday" for that month and because of the importance to obtain this data for an international meeting we proceeded to trouble shoot the assay. The results from our work and later substantiate by the manufacturer, was that IDS antiosteoclast antigen AE-4002 does not work with FFPE and the company has removed this application to it's documentation. To resolve the issue of identifying osteoclasts we have obtained anti-Calcitonin receptor (Serotec MCA2191) and Cathepsin K (IDS AE-3002).
We have yet to evaluate these antibodies and would like to use them in a double-stain assay (BioCare) with IL-1 RI. 
E. CONCLUSIONS:
In efforts to elucidate the mechanism of HBC-induced interactions between breast cancer and stromal or osteoblastic cells induce osteoclastogenesis in vitro through modulating RANKL expression [4] . Therefore, PTHrP does not directly influence osteoclasts, but supports osteoclastogenesis indirectly through the upregulation of RANKL on osteoblasts. Additionally, during bone resorption, transforming growth factor beta (TGF[) is released from the bone matrix and stimulates breast carcinoma cells to produce additional PTHrP, which in turn, perpetuates osteoclast-mediated HBC-IO ( Figure  2 ). Although this model represents the current paradigm, it primarily derived from animal and tissue culture studies. Recent human studies dispute this mechanism for the activation of osteoclasts. Examining various osteolytic human bone tumors for RANK-L expression, Good et. al. were unable to show expression in breast metastasis [5] . In a larger study of 42 samples of human breast cancer bone metastasis, no evidence of RANK-L expression was observed on breast cancer cells, however osteoblasts were not evaluated (personal communication: Dr. Pardieb Bhatia, University of Connecticut Health Center). Clearly, other models of HBCinduced osteolysis must be explored.
We are the first to demonstrate the expression of Interleukin-1 (IL-1) by human breast carcinoma (HBC) cells and the expression of the IL-1Receptor-I on osteoclasts at the site of osteolysis in human bone samples (appendix) [6] . Furthermore, we have shown with cell lines that IL-1, acting through it's receptor on HBC cells, 8
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Tregulates the autocrine activation of the tumor cell mitogen and angiogenesis factor, IL-8 [7, 8] . Based on our work and the literature, we hypothesize that HBC cells can directly regulate osteoclasts (and therefore osteolysis) by the IL-1 network and that IL-1 up-regulates HBC IL-8 autocrine expression. The expression of IL-8, in-turn, augments tumor angiogenesis through IL-8 Receptors on vascular endothelial cells (Figure 3) . IL-1 has been demonstrated in bone resorption and IL-I has been shown to be expressed by HBC cells, however a major gap exists in our understanding of processes that occur in HBC-Induced Osteolysis and the role of tumorcell derived IL-1. El. "SO WHAT". 1. This work demonstrates a previously unrecognized pathway (IL-1) in breast cancer-induced osteolysis, which is distinct and independent of the PTHrP model as described above in figure 2. 2. This work supports our hypothesis as described in figure 3 and suggests direct activation of osteoclasts by breast cancer derived IL-1. 2. This work is based on human samples and has direct relevance to human pathophysiology. 3. The PTHrP model is primary derived from animal and tissue culture studies. Our studies suggest that the currently used animal models of breast cancer osseous metastatic pathology my not be a true representation of the human disease. 4. Human breast cancer bone metastasis occurs in over 80% of patients with advanced breast cancer. Patients diagnosed with osseous-metastatic disease are considered terminal. Over the last few years the prognosis for patients with HBC bone metastasis has nearly doubled from less that a year to 18-24 months. As we are better able to treat patients, we must also hold out hope to those with advanced disease. With bone metastasis there is a significant decrease in the quality of life due to severe pain and complications associated with pathological fracture. Current palliative treatment consists of using bisphophonates, which decrease osteolysis, but has little effect on tumor and disease progression in the osseous metastatic lesion. Based on our work in orthopaedic oncology using human tissue, we developed the hypotheses that HBC-derived IL-1 mediates osteolysis by differentiation and activation of osteoclasts through the IL-1 Receptor. With this work, we have identified a new network of cytokines and receptors that contribute to disease progression. Identification of this pathway is the first step in developing new therapeutic. Bone metastasis in human breast carcinoma (HBC) occurs in 83% of patients with advanced disease. Breast cancer has a predilection for spreading to the bone and bone metastasis is a major cause of increased pain, morbidity and mortality. Clinically, bone metastasis causes degeneration of the bone matrix (osteolysis), hypercalcemia, pathologic fracture, and nerve-compression syndrome. The pathophysiology of human breast carcinoma-induced osteolysis (HBC-IO) involves an increase in the number and activity of osteoclasts within the HBC metastatic lesion. These observations strongly support the involvement of cell-to-cell interactions and cytokine networks. We have recently demonstrated that the expression of the proinflammatory IL-1 family of cytokines and receptors correlates with disease severity and induction of the pro-angiogenic and mitogenic cytokine, IL-8, in HBC primary tumor. Furthermore, IL-8, a product of HBC IL-1 stimulation, has recently been shown to have a greater correlation with HBC bone metastatic potential than PTHrP in the nude mouse. Since IL-1 expression has been correlated with HBC aggressiveness and IL-1 is a known activator of osteoclasts, we examined the expression of the IL-I family of cytokines and receptors and IL-8 in HBC-IO using archival human samples and immunohistochemistry. Histologic sections from pathological fracture resection or biopsy of HBC metastasis to bone from patients (mean age, 52yrs; age range, 34-83yrs; no prior radiation to site) were analyzed. We observed IL-1 and IL-8 expression by HBC cells and IL-1Receptor I expression on osteoclasts (Table 1 ). These data suggest that HBC-derived IL-1 is an important mediator of human breast cancer-induced osteolysis and supports our hypothesis: 1. IL-1 can activate osteoclastogenesis, promote osteoclast (OC) activation and osteolysis via paracrine induction of IL-1Receptors on osteoclasts. 2. IL-1 can promote tumor progression by 
